Lenacapavir, a twice-yearly injectable PrEP medication, was proven to be completely effective in preventing HIV infection in cisgender women. Developed by Gilead Sciences, this is the first HIV prevention drug that resulted in zero new human infections during Phase 3 trials. Lenacapavir holds great promise for the future of HIV prevention, as it represents an alternative that can mitigate challenges of adherence and stigma associated with a daily oral tablet PrEP regimen.